We are pleased to announce that Global Clinical Trials (GCT) has been awarded a new clinical study in social anxiety disorder by a leading biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders.
This U.S.-based study will be conducted across 30 sites, with GCT serving as the CRO, managing study operations from site selection and startup through clinical monitoring to site closure.
Social anxiety disorder remains a highly prevalent and often underdiagnosed condition, significantly impacting quality of life. We are proud to support the sponsor in evaluating new therapeutic options for those living with this condition.